7ZQ8 | pdb_00007zq8

VelcroVax tandem HBcAg with SUMO-Affimer inserted at MIR (T=4 VLP)


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.90 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation 3D Report Full Report

Validation slider image for 7ZQ8

This is version 1.2 of the entry. See complete history

Literature

VelcroVax: a "Bolt-On" Vaccine Platform for Glycoprotein Display.

Kingston, N.J.Grehan, K.Snowden, J.S.Hassall, M.Alzahrani, J.Paesen, G.C.Sherry, L.Hayward, C.Roe, A.Stephen, S.Tomlinson, D.Zeltina, A.Doores, K.J.Ranson, N.A.Stacey, M.Page, M.Rose, N.J.Bowden, T.A.Rowlands, D.J.Stonehouse, N.J.

(2023) mSphere 8: e0056822-e0056822

  • DOI: https://doi.org/10.1128/msphere.00568-22
  • Primary Citation Related Structures: 
    7ZQ8, 7ZQA

  • PubMed Abstract: 

    Having varied approaches to the design and manufacture of vaccines is critical in being able to respond to worldwide needs and newly emerging pathogens. Virus-like particles (VLPs) form the basis of two of the most successful licensed vaccines (against hepatitis B virus [HBV] and human papillomavirus). They are produced by recombinant expression of viral structural proteins, which assemble into immunogenic nanoparticles. VLPs can be modified to present unrelated antigens, and here we describe a universal "bolt-on" platform (termed VelcroVax) where the capturing VLP and the target antigen are produced separately. We utilize a modified HBV core (HBcAg) VLP with surface expression of a high-affinity binding sequence (Affimer) directed against a SUMO tag and use this to capture SUMO-tagged gp1 glycoprotein from the arenavirus Junín virus (JUNV). Using this model system, we have solved the first high-resolution structures of VelcroVax VLPs and shown that the VelcroVax-JUNV gp1 complex induces superior humoral immune responses compared to the noncomplexed viral protein. We propose that this system could be modified to present a range of antigens and therefore form the foundation of future rapid-response vaccination strategies. IMPORTANCE The hepatitis B core protein (HBc) forms noninfectious virus-like particles, which can be modified to present a capturing molecule, allowing suitably tagged antigens to be bound on their surface. This system can be adapted and provides the foundation for a universal "bolt-on" vaccine platform (termed VelcroVax) that can be easily and rapidly modified to generate nanoparticle vaccine candidates.


  • Organizational Affiliation
    • Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.

Macromolecule Content 

  • Total Structure Weight: 105.59 kDa 
  • Atom Count: 4,329 
  • Modeled Residue Count: 540 
  • Deposited Residue Count: 948 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
VelcroVax tandem HBcAg with SUMO-Affimer inserted at MIR
A, B
474synthetic constructMutation(s): 0 

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.90 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Medical Research Council (MRC, United Kingdom)United KingdomMR/P022626/1
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)United StatesR01 AI 169457-0
Wellcome TrustUnited Kingdom204825/Z/16/Z
Wellcome TrustUnited Kingdom102174/B/13/Z

Revision History  (Full details and data files)

  • Version 1.0: 2023-01-18
    Type: Initial release
  • Version 1.1: 2023-08-09
    Changes: Database references
  • Version 1.2: 2024-10-09
    Changes: Data collection, Structure summary